Codexis Inc (Codexis) is a protein engineering company that discovers, develops, and markets synthetic proteins and biocatalysts for the pharmaceutical, biotherapeutics, and fine chemicals markets for use in molecular diagnostics.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company's research and development initiatives focus on engineering biocatalysts, bioprocess development, cellular engineering, biocatalyst screening, metabolites, strain improvement, fermentation development, and process engineering. The company conducts enzyme evolution, enzyme production development, microbial bioprocess development, microbial evolution, and process engineering evaluations and design primarily at its headquarters in Redwood City, California. Codexis also applies its CodeEvolver technology platform to develop customized enzymes for various molecular biology applications, including template-dependent mRNA manufacturing, next-generation sequencing, diagnostic testing, and DNA oligonucleotide synthesis. As of December 31,2025, Codexis owned approximately 1,600 active issued patents and pending patent applications in the US and various foreign jurisdictions. The company has approximately 92 trademark registrations in the US and foreign jurisdictions. Codexis has entered into technology alliances, including a license agreement with Pfizer and a non-exclusive commercial and manufacturing license agreement with Alphazyme LLC. In FY2025, the company spent US$52.3 million on its R&D activities, which as a percentage of revenue stood at 74.3% and grew 13% YoY. The company employed 45 personnel in its R&D department in FY2025.